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Summary We report a case of lymphadenitis due to Rhodotorula mucilaginosa in a man with
well-controlled HIV infection. The diagnosis was established microbiologically by positive lymph
tissue cultures, and clinically by responses of lymphadenitis to antifungal therapy. The patient
was asymptomatic and was treated with itraconazole 200 mg orally once daily as an outpatient.
Clinical response was evident within three weeks with improvement of lymphadenopathy on
serial computed tomography scans. Lymphadenopathy resolved completely after 8 months of
itraconazole therapy and had not recurred 9 months after treatment was stopped.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.Introduction
Rhodotorula is a basidiomycetous yeast belonging to the
family Cryptococcaceae.1 It is characterized by the produc-
tion of carotenoid torularhodin, a pigment that gives their
colonies the typical salmon-pink to coral-red appearance
(hence the common name, ‘red yeast’).2 Rhodotorula species
are ubiquitous and have been recovered from human skin,
nails, conjunctiva, the respiratory, gastrointestinal and urin-
ary tracts, as well as various environmental sources such as* Corresponding author. Tel.: +1 718 584 9000x5048;
fax: +1 718 741 4406.
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doi:10.1016/j.ijid.2008.04.006soil and water. They are generally considered to be non-
pathogenic commensals or contaminants. Their pathogenic
potential has only been recognized during the past decade.3
Infections due to Rhodotorula spp are uncommon with less
thanahundredcases reported in theEnglish literatureover the
past 40 years.2,4 The majority of cases were fungemias in
patients with central venous catheters, but other infections
such as meningitis, ventriculitis, endocarditis, peritonitis,
dacryocystitis, keratitis, and endophthalmitis have been
reported.2,5 Among the Rhodotorula spp that have been
described as human pathogens, Rhodotorula glutinis and Rho-
dotorula mucilaginosa (formerly known as Rhodotorula rubra
orRhodotorulapilimanae) are themostcommon species.1,4,6,7
Immunosuppression and the use of an indwelling catheter are
the major risk factors for Rhodotorula infections.2,4,6,8Society for Infectious Diseases.
Figure 1 Salmon-pink colonies of Rhodotorula mucilaginosa
from biopsied lymph nodes on Sabouraud-dextrose agar.
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We describe a case of R. mucilaginosa lymphadenitis in a
patient with HIV infection. The patient was a 46-year-old
African-American man with a past medical history significant
for anemia, chronic renal insufficiency, shingles, toxoplasmic
encephalitis, and HIV infection. He had no known drug
allergies. The patient had been diagnosed two years pre-
viously with Toxoplasma encephalitis and AIDS with a nadir
CD4 cell count of 40 cells/mm3, and had been on effective
antiretroviral therapy ever since. His past antiretroviral regi-
mens, in chronological order, included zidovudine/lamivu-
dine/indinavir (8 months), stavudine/lamivudine/indinavir
(3 months), stavudine/lamivudine/abacavir (1 month), and
zidovudine/lamivudine/abacavir (8 months). Changes in his
antiretroviral regimen were prompted by adverse drug reac-
tions including anemia, nephrolithiasis, and peripheral neu-
ropathy rather than poor viral control. He tolerated his
current regimen (abacavir 300 mg twice daily, lamivudine
150 mg twice daily, and efavirenz 600 mg once daily) well
without any adverse effects. For one year before presenta-
tion, his HIV disease was well controlled by this regimen with
viral loads ranging from <50 copies/mL to 1781 copies/mL
and CD4 cell% ranging from 23% to 27%. His CD4 cell counts
had been consistently >200 cells/mm3 for more than two
years.
The patient presented to the infectious diseases clinic for
a routine follow-up visit. Upon presentation, he was afebrile
and had a respiratory rate of 16 breaths/minute, a heart rate
of 92 beats/minute, and a blood pressure of 140/80 mmHg.
The patient felt well in general and had had a 30-lb (13.6-kg)
weight gain over the past 6 months. Physical examinations
revealed a firm, non-tender swelling of 3—4 cm in diameter in
the right neck below the thyroid gland. A computed tomo-
graphy (CT) scan of the neck was ordered and subsequently
showed a 5  4  6 cm lobulated lesion consistent with lym-
phadenopathy in the medial right supraclavicular region,
effacing the right thyroid gland and displacing the trachea
to the left. An incisional biopsy of the neck mass was per-
formed and two lymph nodes were sent for evaluation: one to
the pathology laboratory for histocytology studies and one to
the microbiology laboratory for Gram-stained smear, KOH
fungal prep, and acid-fast bacillus (AFB) smear, as well as
bacterial, fungal, viral, and AFB cultures. While no yeasts
were seen with special stains on histocytology studies of one
lymph node, direct plating of the other lymph node on
Sabouraud-dextrose agar grew many colonies of R. mucila-
ginosa in 5 days (Figure 1). Identity of the isolate was
confirmed by Vitek automated system for identification
and API manual biochemical tests (BioMerieux Diagnostics).
Examinations of the Gram-stained smear, KOH fungal prep,
and AFB smear of the specimen were unremarkable. All other
cultures were negative. The patient was diagnosed with R.
mucilaginosa lymphadenitis, and itraconazole 200 mg orally
once daily was immediately initiated. Three weeks into
treatment, a follow-up CT scan of the neck revealed mild
improvement of the right supraclavicular lymphadenopathy
that measured 5  4  5 cm (previously 5  4  6 cm). Ther-
apy with itraconazole was continued for a total of 8 months
during which time the neck swelling resolved. The patient
tolerated itraconazole treatment well without adverseeffects. His liver enzymes remained normal throughout treat-
ment. There was no evidence of clinical relapse 2 months
after the discontinuation of itraconazole. His HIV disease
remained well controlled on abacavir/lamivudine/efavirenz
with low-grade viremias (<1000 copies/mL) and CD4 cell
counts >800 cells/mm3.
Discussion
For a long time, Rhodotorula was considered to be a non-
pathogenic, ubiquitous contaminant. Its pathogenic poten-
tial has only been recognized during the past decade.9
Infections due to Rhodotorula spp are usually opportunistic,
occurring predominantly in immunocompromised patients
with a central venous catheter.1,9 In a case series of 43
patients with Rhodotorula fungemias reported in the litera-
ture between 1960 and 2000, 42 patients had a central
venous catheter and 33 patients had either an underlying
malignancy or a diagnosis of AIDS.4 Broad-spectrum antibio-
tics, corticosteroids, hyperalimentation, surgery, chronic
renal failure, diabetes mellitus, granulocytopenia, and
damage to skin and mucosa have also been suggested as
predisposing factors for Rhodotorula infections.2,4,8 Our
patient was HIV-infected and his infection was apparently
well controlled with low grade viremia (<1000 copies/mL)
and CD4 cell counts persistently greater than 200 cells/mm3
before presentation. He also had mild chronic renal insuffi-
ciency with serum creatinine values ranging from 115 mmol/L
to 203 mmol/L for the past year. HIV infection and possibly
chronic renal insufficiency could have predisposed our
patient to Rhodotorula infections.
Rhodotorula appears to be less virulent than other patho-
genic yeasts, but there is a 15% mortality rate for systemic
infections.2 In addition to fungemias, Rhodotorula has been
reported to be the causative agent for a wide variety of
infections including meningitis, ventriculitis, endocarditis,
peritonitis, dacryocystitis, keratitis, and endophthalmitis.2,5
We report a suspected case of lymphadenitis caused by R.
Rhodotorula mucilaginosa lymphadenitis e29mucilaginosa. Although the diagnosis could not be confirmed
without observing R. mucilaginosa on histocytology studies,
it was established microbiologically by positive cultures from
the lymph node, and clinically by responses of lymphadenitis
to antifungal therapy. Unlike other Rhodotorula infections
that usually present with fevers,2 our patient was asympto-
matic. The absence of symptoms in our patient was probably
due to the sequestration of R.mucilaginosa in the lymph node
tissues.
Susceptibility data on Rhodotorula spp are scarce, but
they appear to be generally more susceptible to amphoter-
icin B and flucytosine than to the azole and echinocandin
antifungal agents.6 Zaas et al.6 and Espinel-Ingroff10 studied
the susceptibility of a total of 13 strains of R. mucilaginosa
and two strains of R. glutinis. The tested strains were
susceptible to amphotericin B (minimum inhibitory concen-
tration (MIC) range 0.25—1.0 mg/mL) and flucytosine (MIC
range 0.125—0.25 mg/mL), intermediate to itraconazole (MIC
range 0.25—4.0 mg/mL) and voriconazole (MIC range 0.25—
8.0 mg/mL), and resistant to fluconazole (MIC range 32—
>64 mg/mL) and caspofungin (MIC range 16—>16 mg/mL).
However, it must be noted that methods for antifungal
susceptibility testing are currently not standardized, and
results of in vitro testing do not necessarily correlate with
clinical outcomes. Susceptibility testing for fungi is not
performed at our institution. Our patient was minimally
symptomatic following incisional biopsy and therefore was
treated with oral itraconazole as an outpatient. Clinical
response was evident within three weeks and verified by
improvement of lymphadenopathy on serial CT scans.
The appropriate duration of treatment for Rhodotorula
infections has not been determined. Depending on the nature
of the infections, treatment durations of two weeks to
several months have been proposed.11 Our patient was trea-
ted with itraconazole for 8 months until the swelling (lym-
phadenopathy) was clearly resolved. Lymphadenopathy was
no longer noticeable on physical examinations 2 months after
and had not recurred 9 months after treatment was stopped.
To our knowledge, this could be the first case report of
lymphadenitis due to R. mucilaginosa. The patient had no
other predisposing history such as an indwelling intravenous
catheter or hospitalization receiving intravenous therapies
for at least one year prior to this event. The only predisposing
risk factor was his immunologic status due to HIV infection,which was well controlled. Although R. mucilaginosa lym-
phadenitis in our patient was successfully treated with 8
months of itraconazole, the optimal antifungal agent and
duration of treatment for this infection in an outpatient
setting has not been established. Infections due to Rhodotor-
ula spp are rare, yet clinicians should maintain a high index of
suspicion for such opportunistic yeast infections in immuno-
compromised patients.
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